	US 12,351,844 B2
	Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes
Henry M. Colecraft, Robbinsville, NJ (US); and Scott Kanner, New York, NY (US)
Assigned to The Trustees of Columbia University in the City of New York, New York, NY (US)
Filed by THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, New York, NY (US)
Filed on Aug. 21, 2024, as Appl. No. 18/811,674.
Application 18/811,674 is a division of application No. 18/501,967, filed on Nov. 3, 2023, granted, now 12,091,695.
Application 18/501,967 is a division of application No. 16/867,923, filed on May 6, 2020, granted, now 11,845,967, issued on Dec. 19, 2023.
Application 16/867,923 is a continuation in part of application No. PCT/US2018/059229, filed on Nov. 5, 2018.
Claims priority of provisional application 62/582,108, filed on Nov. 6, 2017.
Prior Publication US 2024/0409913 A1, Dec. 12, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/64 (2006.01); A61K 38/00 (2006.01); C12N 15/85 (2006.01); C12Q 1/6883 (2018.01)

CPC C12N 9/6472 (2013.01) [C12N 15/85 (2013.01); C12Q 1/6883 (2013.01); C12Y 304/22 (2013.01); A61K 38/00 (2013.01); C12Q 2600/156 (2013.01)]

30 Claims

1. A method of treating or ameliorating the effects of a disease in a human subject, the method comprising administering to the subject a nucleic acid molecule encoding a recombinant engineered deubiquitinase (DUB) comprising:

a) a catalytic unit comprising the catalytic domain of a deubiquitinase;

b) a protein binder comprising an antibody, or antigen binding fragment thereof, that specifically binds a target substrate protein for deubiquitination by the engineered DUB; and

c) a variable linker between the catalytic unit and the protein binder, and

wherein the disease is cystic fibrosis, long QT syndrome, Brugada syndrome, Bartter Syndrome, or epilepsy.